Drug Details
| General Information of the Drug (ID: DR6061) | ||||
|---|---|---|---|---|
| Name |
Lenalidomide
|
|||
| Synonyms |
Lenalidomide; 191732-72-6; Revlimid; Revimid; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CC-5013; Lenalidomide (CC-5013); CDC 501; IMiD3; CC 5013; CDC-501; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Revlimid (TN); CHEBI:63791; C13H13N3O3; MFCD07772307; 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; NCGC00167491-01; 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione; DSSTox_CID_26664; DSSTox_RID_81806; DSSTox_GSID_46664; Revlimid (lenalidomide); 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione; CAS-191732-72-6; Lenalidomide (USAN/INN); Lenadoamide; Lenalidomide [USAN:INN:BAN]; (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; ENMD 0997; ENMD-0997; HSDB 8220; IMID-5013; CDC-5013; ALBB-015321; 1227162-34-6; PubChem19113; CHEMBL848; Revlimid (TN) (Celgene); SCHEMBL32978; MLS003899194; GTPL7331; SCHEMBL1980410; 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione; DTXSID8046664; BDBM65454; 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (3S)-; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; BCPP000186; HMS3654G07; HMS3674C05; BCP01390; HY-A0003; Revlimid, Lenalidomide, CC-5013; SYP-1512; Tox21_112492; ABP001089; AC-914; NSC747972; s1029; STK639603; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; AKOS005146276; AKOS005174869; Tox21_112492_1; ACN-034469; BCP9000847; CCG-264781; CS-0125; DB00480; KS-1207; MCULE-9771679074; NSC 747972; NSC-747972; NCGC00167491-02; NCGC00167491-03; NCGC00167491-04; AK-47482; SMR002529986; SY047646; AB0017965; AM20050439; FT-0659651; FT-0670758; FT-0670759; SW218084-2; T5245; EC-000.2340; D04687; S-4172; AB01273975-01; AB01273975-02; AB01273975_03; 732L726; Q425681; SR-01000883999; Q-101410; SR-01000883999-1; Z1741976709; 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)-2,6-piperidinedione; 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-dioxopiperidine; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione; 4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one; 443912-14-9
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Multiple myeloma [ICD-11: 2A83] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability
Elimination
66% of drug is excreted from urine in the unchanged form
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.375 micromolar/kg/day
Water Solubility
The ability of drug to dissolve in water is measured as 0.00045 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C13H13N3O3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
|
|||
| InChI |
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
|
|||
| InChIKey |
GOTYRUGSSMKFNF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 191732-72-6
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL10 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BC-3 | CVCL_1080 | Primary effusion lymphoma | Homo sapiens | ||
| BCBL-1 | CVCL_0165 | Primary effusion lymphoma | Homo sapiens | |||
| In-vivo Model | Six to eight week old immuno-compromised male or female NOD/SCID mice were inoculated with 2 million BC-3 or BCBL-1 cells. | |||||
| Experimental
Result(s) |
Lenalidomide in combination with arsenic trioxide is an effective therapy for primary effusion lymphoma. | |||||
| Tanshinone I | Salvia miltiorrhiza | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ACD | Molecule Info | ||
| Down-regulation | Expression | TERF2IP | Molecule Info | |||
| Down-regulation | Expression | TNKS-1 | Molecule Info | |||
| In-vitro Model | RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
| U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Tumor necrosis factor (TNF) | Molecule Info | [4] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | Cytokine-cytokine receptor interaction | |||
| 3 | NF-kappa B signaling pathway | |||
| 4 | Sphingolipid signaling pathway | |||
| 5 | mTOR signaling pathway | |||
| 6 | Apoptosis | |||
| 7 | TGF-beta signaling pathway | |||
| 8 | Osteoclast differentiation | |||
| 9 | Antigen processing and presentation | |||
| 10 | Toll-like receptor signaling pathway | |||
| 11 | NOD-like receptor signaling pathway | |||
| 12 | RIG-I-like receptor signaling pathway | |||
| 13 | Hematopoietic cell lineage | |||
| 14 | Natural killer cell mediated cytotoxicity | |||
| 15 | T cell receptor signaling pathway | |||
| 16 | Fc epsilon RI signaling pathway | |||
| 17 | TNF signaling pathway | |||
| 18 | Adipocytokine signaling pathway | |||
| 19 | Type II diabetes mellitus | |||
| 20 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 21 | Type I diabetes mellitus | |||
| 22 | Alzheimer's disease | |||
| 23 | Amyotrophic lateral sclerosis (ALS) | |||
| 24 | Pertussis | |||
| 25 | Legionellosis | |||
| 26 | Leishmaniasis | |||
| 27 | Chagas disease (American trypanosomiasis) | |||
| 28 | African trypanosomiasis | |||
| 29 | Malaria | |||
| 30 | Toxoplasmosis | |||
| 31 | Amoebiasis | |||
| 32 | Tuberculosis | |||
| 33 | Hepatitis C | |||
| 34 | Hepatitis B | |||
| 35 | Influenza A | |||
| 36 | HTLV-I infection | |||
| 37 | Herpes simplex infection | |||
| 38 | Proteoglycans in cancer | |||
| 39 | Asthma | |||
| 40 | Inflammatory bowel disease (IBD) | |||
| 41 | Systemic lupus erythematosus | |||
| 42 | Rheumatoid arthritis | |||
| 43 | Allograft rejection | |||
| 44 | Graft-versus-host disease | |||
| 45 | Hypertrophic cardiomyopathy (HCM) | |||
| 46 | Dilated cardiomyopathy | |||
| NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
| 2 | IL2 Signaling Pathway | |||
| 3 | IL3 Signaling Pathway | |||
| 4 | IL4 Signaling Pathway | |||
| 5 | Leptin Signaling Pathway | |||
| 6 | RANKL Signaling Pathway | |||
| 7 | IL1 Signaling Pathway | |||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | Wnt signaling pathway | |||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
| Pathway Interaction Database | IL27-mediated signaling events | Click to Show/Hide | ||
| 2 | Canonical NF-kappaB pathway | |||
| 3 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 4 | Angiopoietin receptor Tie2-mediated signaling | |||
| 5 | Signaling events mediated by HDAC Class I | |||
| 6 | TNF receptor signaling pathway | |||
| 7 | Ceramide signaling pathway | |||
| 8 | amb2 Integrin signaling | |||
| 9 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 10 | IL23-mediated signaling events | |||
| 11 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 12 | Caspase Cascade in Apoptosis | |||
| 13 | Cellular roles of Anthrax toxin | |||
| 14 | Downstream signaling in naï | |||
| 15 | ||||
| Reactome | Transcriptional regulation of white adipocyte differentiation | Click to Show/Hide | ||
| 2 | TNFR1-induced proapoptotic signaling | |||
| 3 | Regulation of TNFR1 signaling | |||
| 4 | TNFR1-induced NFkappaB signaling pathway | |||
| 5 | TNFR1-mediated ceramide production | |||
| 6 | TNFR2 non-canonical NF-kB pathway | |||
| 7 | TNF signaling | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | Monoamine Transport | |||
| 3 | SIDS Susceptibility Pathways | |||
| 4 | TGF Beta Signaling Pathway | |||
| 5 | Cytokines and Inflammatory Response | |||
| 6 | MAPK Signaling Pathway | |||
| 7 | EV release from cardiac cells and their functional effects | |||
| 8 | FAS pathway and Stress induction of HSP regulation | |||
| 9 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 10 | Cardiac Hypertrophic Response | |||
| 11 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 12 | Aryl Hydrocarbon Receptor | |||
| 13 | Apoptosis | |||
| 14 | Nanoparticle triggered regulated necrosis | |||
| 15 | Amyotrophic lateral sclerosis (ALS) | |||
| 16 | Adipogenesis | |||
| 17 | Allograft Rejection | |||
| 18 | TNF alpha Signaling Pathway | |||
| 19 | TWEAK Signaling Pathway | |||
| 20 | Extrinsic Pathway for Apoptosis | |||
| 21 | Folate Metabolism | |||
| 22 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 23 | Vitamin B12 Metabolism | |||
| 24 | Selenium Micronutrient Network | |||
| 25 | Regulation of toll-like receptor signaling pathway | |||
| 26 | Matrix Metalloproteinases | |||